References
- Bader, R. (1994). Atoms in Molecules: A Quantum Theory. Oxford University Press.
- Bader, R. F. W. (1991). A quantum theory of molecular structure and its applications. Chemical Reviews, 91(5), 893–928. https://doi.org/https://doi.org/10.1021/cr00005a013
- Bartashevich, E., Matveychuk, Y., & Tsirelson, V. (2019). Identification of the tetrel bonds between halide anions and carbon atom of methyl groups using electronic criterion. Molecules, 24(6), 1083. https://doi.org/https://doi.org/10.3390/molecules24061083
- Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The protein data bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/https://doi.org/10.1093/nar/28.1.235
- Bytheway, I., Darley, M. G., & Popelier, P. L. A. (2008). The calculation of polar surface area from first principles: An application of quantum chemical topology to drug design. ChemMedChem, 3(3), 445–453. https://doi.org/https://doi.org/10.1002/cmdc.200700262
- Clark, D. E. (2011). What has polar surface area ever done for drug discovery? Future Medicinal Chemistry, 3(4), 469–484. https://doi.org/https://doi.org/10.4155/fmc.11.1
- Conconi, M. T., Marzaro, G., Urbani, L., Zanusso, I., Di Liddo, R., Castagliuolo, I., Brun, P., Tonus, F., Ferrarese, A., Guiotto, A., & Chilin, A. (2013). Quinazoline-based multi-tyrosine kinase inhibitors: Synthesis, modeling, antitumor and antiangiogenic properties. European Journal of Medicinal Chemistry, 67, 373–383. https://doi.org/https://doi.org/10.1016/j.ejmech.2013.06.057
- Dassault Systèmes BIOVIA. (2017). Discovery Studio Modeling Environment 2016. Dassault Systèmes.
- De Bono, J. S., & Ashworth, A. (2010). Translating cancer research into targeted therapeutics. Nature, 467(7315), 543–549. https://doi.org/https://doi.org/10.1038/nature09339
- de La Motte Rouge, T., Galluzzi, L., Olaussen, K. A., Zermati, Y., Tasdemir, E., Robert, T., Ripoche, H., Lazar, V., Dessen, P., Harper, F., Pierron, G., Pinna, G., Araujo, N., Harel-Belan, A., Armand, J.-P., Wong, T. W., Soria, J. C., & Kroemer, G. (2007). A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Research, 67(13), 6253–6262. https://doi.org/https://doi.org/10.1158/0008-5472.CAN-07-0538
- Ganjoo, K. N., & Wakelee, H. (2007). Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics: Targets & Therapy, 1(4), 335–346. PMID: 19707304
- Higa, G. M., & Abraham, J. (2007). Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy, 7(9), 1183–1192. https://doi.org/https://doi.org/10.1586/14737140.7.9.1183
- Huber, M., & Huber, B. (2019). Innovation in oncology drug development. Journal of Oncology, 1–16. https://doi.org/https://doi.org/10.1155/2019/9683016
- Kawakita, Y., Seto, M., Ohashi, T., Tamura, T., Yusa, T., Miki, H., Iwata, H., Kamiguchi, H., Tanaka, T., Sogabe, S., Ohta, Y., & Ishikawa, T. (2013). Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors. Bioorganic & Medicinal Chemistry, 21(8), 2250–2261. https://doi.org/https://doi.org/10.1016/j.bmc.2013.02.014
- Li, T., Ling, Y.-H., Goldman, I. D., & Perez-Soler, R. (2007). Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 13(11), 3413–3422. https://doi.org/https://doi.org/10.1158/1078-0432.CCR-06-2923
- Liu, T., Lin, Y., Wen, X., Jorissen, R. N., & Gilson, M. K. (2007). BindingDB: A web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Research, 35(Database issue), D198–D201. https://doi.org/https://doi.org/10.1093/nar/gkl999
- Li, B., Xie, X., Chen, Z., Zhan, C., Zeng, F., & Wu, S. (2018). Tumor inhibition achieved by targeting and regulating multiple key elements in EGFR signaling pathway using a self-assembled nanoprodrug. Advanced Functional Materials, 28(22), 1-15. https://doi.org/https://doi.org/10.1002/adfm.201800692
- Macrae, C. F., Bruno, I. J., Chisholm, J. A., Edgington, P. R., McCabe, P., Pidcock, E., Rodriguez-Monge, L., Taylor, R., van de Streek, J., & Wood, P. A. (2008). Mercury CSD 2.0 – New features for the visualization and investigation of crystal structures. Journal of Applied Crystallography, 41(2), 466–470. https://doi.org/https://doi.org/10.1107/S0021889807067908
- Mendelsohn, J., & Baselga, J. (2006). Epidermal growth factor receptor targeting in cancer. Seminars in Oncology, 33(4), 369–385. https://doi.org/https://doi.org/10.1053/j.seminoncol.2006.04.003
- Padma, V. V. (2015). An overview of targeted cancer therapy. BioMedicine, 5(4), 1–6. https://doi.org/https://doi.org/10.7603/s40681-015-0019-4
- Pathak, P., Naumovich, V., Grishina, M., Shukla, P. K., Verma, A., & Potemkin, V. (2019). Quinazoline based 1,3,5‐triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: Design, synthesis, docking, and QSAR study. Archiv Der Pharmazie, 352(9), 1–18. https://doi.org/https://doi.org/10.1002/ardp.201900053
- Pathak, P., Shukla, P. K., Kumar, V., Kumar, A., & Verma, A. (2018). Quinazoline clubbed 1,3,5-triazine derivatives as VEGFR2 kinase inhibitors: Design, synthesis, docking, in vitro cytotoxicity and in ovo antiangiogenic activity. Inflammopharmacology, 26(6), 1441–1453. https://doi.org/https://doi.org/10.1007/s10787-018-0471-3
- Peng, Y.-H., Shiao, H.-Y., Tu, C.-H., Liu, P.-M., Hsu, J. T.-A., Amancha, P. K., Wu, J.-S., Coumar, M. S., Chen, C.-H., Wang, S.-Y., Lin, W.-H., Sun, H.-Y., Chao, Y.-S., Lyu, P.-C., Hsieh, H.-P., & Wu, S.-Y. (2013). Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: The role of the DFG motif in the design of epidermal growth factor receptor inhibitors. Journal of Medicinal Chemistry, 56(10), 3889–3903. https://doi.org/https://doi.org/10.1021/jm400072p
- Perozzo, R., Folkers, G., & Scapozza, L. (2004). Thermodynamics of protein-ligand interactions: history, presence, and future aspects. Journal of Receptor and Signal Transduction Research, 24(1–2), 1–52. https://doi.org/https://doi.org/10.1081/rrs-120037896
- Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera – a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612. https://doi.org/https://doi.org/10.1002/jcc.20084
- Potemkin, V. A., & Grishina, M. A. (2008). A new paradigm for pattern recognition of drugs. Journal of Computer-Aided Molecular Design, 22, 489–505. https://doi.org/https://doi.org/10.1007/s10822-008-9203-x
- Potemkin, V., & Grishina, M. (2018a). Chemosophia. Czech Republic. www.chemosophia.com
- Potemkin, V., & Grishina, M. (2018b). Grid-based technologies for in silico screening and drug design. Current Medicinal Chemistry, 25(29), 3526–3537. https://doi.org/https://doi.org/10.2174/0929867325666180309112454
- Potemkin, A. V., Grishina, M. A., & Potemkin, V. A. (2017). Grid-based continual analysis of molecular interior for drug discovery, QSAR and QSPR. Current Drug Discovery Technologies, 14(3), 181–205. https://doi.org/https://doi.org/10.2174/1570163814666170207144018
- Potemkin, V. A., Pogrebnoy, A. A., & Grishina, M. A. (2009). Technique for energy decomposition in the study of “receptor-ligand” complexes. Journal of Chemical Information and Modeling, 49(6), 1389–1406. https://doi.org/https://doi.org/10.1021/ci800405n
- Prabhu, N. V., & Sharp, K. A. (2005). Heat capacity in proteins. Annual Review of Physical Chemistry, 56(1), 521–548. https://doi.org/https://doi.org/10.1146/annurev.physchem.56.092503.141202
- Roskoski, R. (2014). The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological Research, 79, 34–74. https://doi.org/https://doi.org/10.1016/j.phrs.2013.11.002
- Salentin, S., Schreiber, S., Haupt, V. J., Adasme, M. F., & Schroeder, M. (2015). PLIP: Fully automated protein-ligand interaction profiler. Nucleic Acids Research, 43(W1), W443–W447. https://doi.org/https://doi.org/10.1093/nar/gkv315
- Salmina, E., Grishina, M. A., & Potemkin, V. A. (2013). An approximation of the Cioslowski–Mixon bond order indexes using the AlteQ approach. Journal of Computer-Aided Molecular Design, 27(9), 793–805. https://doi.org/https://doi.org/10.1007/s10822-013-9677-z
- Schaftenaar, G., & de Vlieg, J. (2012). Quantum mechanical polar surface area. Journal of Computer-Aided Molecular Design, 26(3), 311–318. https://doi.org/https://doi.org/10.1007/s10822-012-9557-y
- Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015). State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors. Chemical Society Reviews, 44(22), 8238–8259. https://doi.org/https://doi.org/10.1039/C5CS00252D
- Sogabe, S., Kawakita, Y., Igaki, S., Iwata, H., Miki, H., Cary, D. R., Takagi, T., Takagi, S., Ohta, Y., & Ishikawa, T. (2013). Structure-based approach for the discovery of pyrrolo[3,2-d]pyrimidine-based EGFR T790M/L858R mutant inhibitors. ACS Medicinal Chemistry Letters, 4(2), 201–205. https://doi.org/https://doi.org/10.1021/ml300327z
- Syme, N. R., Dennis, C., Phillips, S. E. V., & Homans, S. W. (2007). Origin of heat capacity changes in a “nonclassical” hydrophobic interaction. Chembiochem : A European Journal of Chemical Biology, 8(13), 1509–1511. https://doi.org/https://doi.org/10.1002/cbic.200700281
- Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J., & Gibson, K. H. (2002). ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research, 62(20), 5749–5754.
- Wells, A. (1999). EGF receptor. The International Journal of Biochemistry & Cell Biology, 31(6), 637–643. https://doi.org/https://doi.org/10.1016/S1357-2725(99)00015-1
- William, W. N., Heymach, J. V., Kim, E. S., & Lippman, S. M. (2009). Molecular targets for cancer chemoprevention. Nature Reviews. Drug Discovery, 8(3), 213–225. https://doi.org/https://doi.org/10.1038/nrd2663
- Xu, G., Searle, L. L., Hughes, T. V., Beck, A. K., Connolly, P. J., Abad, M. C., Neeper, M. P., Struble, G. T., Springer, B. A., Emanuel, S. L., Gruninger, R. H., Pandey, N., Adams, M., Moreno-Mazza, S., Fuentes-Pesquera, A. R., Middleton, S. A., & Greenberger, L. M. (2008). Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases. Bioorganic & Medicinal Chemistry Letters, 18(12), 3495–3499. https://doi.org/https://doi.org/10.1016/j.bmcl.2008.05.024
- Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews. Molecular Cell Biology, 2(2), 127–137. https://doi.org/https://doi.org/10.1038/35052073
- Yosaatmadja, Y., Silva, S., Dickson, J. M., Patterson, A. V., Smaill, J. B., Flanagan, J. U., McKeage, M. J., & Squire, C. J. (2015). Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. Journal of Structural Biology, 192(3), 539–544. https://doi.org/https://doi.org/10.1016/j.jsb.2015.10.018